Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer

Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer

BackgroundOur previous study reported the favorable efficacy and good tolerance associated with a modified XELOX adjuvant chemotherapy with eight cycles of capecitabine and six cycles of oxaliplatin for operated stage III colon cancer. The current study aimed to confirm the feasibility of modified X...

Full description

Bibliographic Details
Main Authors: Jianhong Peng, Weihao Li, Wenhua Fan, Wenhao Zhou, Ying Zhu, Xueying Li, Zhizhong Pan, Xiaoping Lin, Junzhong Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Pharmacology
Subjects:
colon cancer
adjuvant chemotherapy
XELOX (CapeOx)
high risk
feasibility
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.583091/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.583091/full

Similar Items